A5047035254- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- Bacterial Infections and Vaccines
- Complement system in diseases
- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Diabetes and associated disorders
- Biochemical and Structural Characterization
- Full-Duplex Wireless Communications
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Ocular Diseases and Behçet’s Syndrome
- Celiac Disease Research and Management
- Muscle metabolism and nutrition
- Muscle Physiology and Disorders
- Nutrition and Health in Aging
- Antenna Design and Analysis
Novartis Institutes for BioMedical Research
2016-2024
Novartis (Switzerland)
2016-2024
The TGF-β family ligands myostatin, GDF11, and activins are negative regulators of skeletal muscle mass, which have been reported to primarily signal via the ActRIIB receptor on thereby induce wasting described as cachexia. Use a soluble ActRIIB-Fc "trap," block myostatin pathway signaling in normal or cachectic mice leads hypertrophy prevention loss, perhaps suggesting that is responsible for growth regulation. Genetic evidence demonstrates however both ActRIIB- ActRIIA-deficient display...
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. 2020, rare cases retinal vasculitis and/or occlusion (RV/RO) were reported, often during first few months after initiation, consistent with possible immunologic pathobiology. This finding was inconsistent preclinical studies in cynomolgus monkeys that demonstrated no drug-related...
Abstract Type 1 diabetes (T1D) is characterized by a chronic, progressive autoimmune attack against pancreas-specific antigens, effecting the destruction of insulin-producing β-cells. Here we show interleukin-2 (IL-2) non-pancreatic target in T1D. Anti-IL-2 autoantibodies, as well T cells specific for single orthologous epitope IL-2, are present peripheral blood non-obese diabetic (NOD) mice and patients with In NOD mice, generation anti-IL-2 autoantibodies genetically determined their titre...
Reactivation of BK polyomavirus (BKPyV) can cause significant kidney and bladder disease in immunocompromised patients. There are currently no effective, BKPyV-specific therapies. MAU868 is a novel, human immunoglobulin (Ig) G1 monoclonal antibody that binds the major capsid protein, VP1, BKPyV with picomolar affinity, neutralizes infection by 4 genotypes (EC
Abstract During bacterial pathogenesis extensive contacts between the human and extracellular proteomes take place. The identification of novel host-pathogen interactions by standard methods using a case-by-case approach is laborious time consuming. To overcome this limitation, we took advantage large libraries recombinant proteins. We applied large-scale protein microarray-based screening on two important pathogens different approaches: (I) 75 proteins were tested 159 spotted Staphylococcus...
A main feature of Wiskott-Aldrich syndrome (WAS) is increased susceptibility to autoimmunity. key contribution B cells development these complications has been demonstrated through studies samples from affected individuals and mouse models the disease, but role WAS protein (WASp) in controlling peripheral tolerance not specifically explored. Here we show that cell responses remain T dependent constitutive WASp-deficient mice, whereas selective WASp deletion germinal center (GCBs) sufficient...
The sole inhibitory Fcγ receptor CD32b (FcγRIIb) is expressed throughout B and plasma cell development on their malignant counterparts. expression cells known to provide a mechanism of resistance rituximab that can be ameliorated with CD32b-blocking antibody. CD32b, therefore, represents an attractive tumor antigen for targeting monoclonal antibody (mAb). To this end, two anti-CD32b mAbs, NVS32b1 NVS32b2, were developed. Their complementarity-determining regions (CDR) bind the Fc binding...
<div>Abstract<p>The sole inhibitory Fcγ receptor CD32b (FcγRIIb) is expressed throughout B and plasma cell development on their malignant counterparts. expression cells known to provide a mechanism of resistance rituximab that can be ameliorated with CD32b-blocking antibody. CD32b, therefore, represents an attractive tumor antigen for targeting monoclonal antibody (mAb). To this end, two anti-CD32b mAbs, NVS32b1 NVS32b2, were developed. Their complementarity-determining regions...
<p>Supplementary Materials and Methods, Tables</p>
<p>Supplementary Figures S1-S9 show CD32b mRNA vs protein expression, preclinical activity of NVS32b1 NVS32b2, differential activation human mouse FcgRs, expression on cell lines and healthy immune cells.</p>
<p>Supplementary Materials and Methods, Tables</p>
<p>Supplementary Figures S1-S9 show CD32b mRNA vs protein expression, preclinical activity of NVS32b1 NVS32b2, differential activation human mouse FcgRs, expression on cell lines and healthy immune cells.</p>
<div>Abstract<p>The sole inhibitory Fcγ receptor CD32b (FcγRIIb) is expressed throughout B and plasma cell development on their malignant counterparts. expression cells known to provide a mechanism of resistance rituximab that can be ameliorated with CD32b-blocking antibody. CD32b, therefore, represents an attractive tumor antigen for targeting monoclonal antibody (mAb). To this end, two anti-CD32b mAbs, NVS32b1 NVS32b2, were developed. Their complementarity-determining regions...